Tasca Therapeutics Corp — Form D/A
Tasca Therapeutics Corp of CAMBRIDGE, MA, a company, filed a Form D amendment with the SEC on 2025-12-01. The offering totals $70.2M, of which $48.1M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2025-12-01
- Form: D/A
- Accession: 0002046762-25-000005
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $70.2M
- Amount sold: $48.1M
- Remaining: $22.1M
- Investors: 9
- Date of first sale: 2024-11-13
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-530757
Issuer
- Name: Tasca Therapeutics Corp
- CIK: 0002046762
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2021
- Address: 55 SPINELLI PLACE, CAMBRIDGE, MA, 02138
- Phone: 617-390-4306
Officers, directors & promoters (8)
| Name | Role | Location |
|---|
| Michael Aberman | Director | Cambridge, MA |
| Milenko Cicmil | Director | Cambridge, MA |
| David Fallace | Director | BOSTON, MA |
| Seth Lieblich | Director | Cambridge, MA |
| Praveen Tipirneni | Director | Cambridge, MA |
| Xu Wu | Director | Cambridge, MA |
| Milenko Cicmil | Executive Officer | Cambridge, MA |
| Drew King | Executive Officer | Cambridge, MA |
Other filings by this issuer (1)
More